QuidelOrtho Co. (NASDAQ:QDEL - Get Free Report) CEO Brian J. Blaser acquired 6,033 shares of the firm's stock in a transaction that occurred on Wednesday, December 11th. The shares were bought at an average cost of $41.42 per share, for a total transaction of $249,886.86. Following the purchase, the chief executive officer now owns 6,033 shares of the company's stock, valued at approximately $249,886.86. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
QuidelOrtho Trading Down 0.6 %
NASDAQ:QDEL opened at $41.35 on Friday. The business's 50-day moving average is $40.04 and its two-hundred day moving average is $40.08. The firm has a market capitalization of $2.78 billion, a PE ratio of -1.48 and a beta of 0.11. QuidelOrtho Co. has a 12 month low of $29.74 and a 12 month high of $75.86. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.38 and a quick ratio of 0.81.
QuidelOrtho (NASDAQ:QDEL - Get Free Report) last released its quarterly earnings results on Thursday, November 7th. The company reported $0.85 EPS for the quarter, topping the consensus estimate of $0.30 by $0.55. The firm had revenue of $727.00 million for the quarter, compared to analyst estimates of $642.16 million. QuidelOrtho had a positive return on equity of 4.24% and a negative net margin of 66.25%. QuidelOrtho's revenue for the quarter was down 2.3% on a year-over-year basis. During the same period in the previous year, the company posted $0.90 EPS. Research analysts predict that QuidelOrtho Co. will post 1.73 earnings per share for the current fiscal year.
Analyst Ratings Changes
Elon to SHOCK the Market By Dec. 31st?
From Paradigm Press | Ad
There’s a little-known backdoor way to play Elon’s “Super-IPO”…
With as little as $50.
Click here to learn all of the details.
QDEL has been the topic of several analyst reports. Craig Hallum raised shares of QuidelOrtho from a "hold" rating to a "buy" rating and raised their price target for the stock from $40.00 to $57.00 in a research note on Thursday, September 5th. Citigroup upgraded shares of QuidelOrtho from a "neutral" rating to a "buy" rating and raised their target price for the stock from $44.00 to $50.00 in a research report on Wednesday. Royal Bank of Canada reiterated an "outperform" rating and issued a $61.00 price target on shares of QuidelOrtho in a report on Friday, August 16th. UBS Group assumed coverage on QuidelOrtho in a research note on Thursday, September 19th. They issued a "neutral" rating and a $50.00 price target on the stock. Finally, William Blair reiterated a "market perform" rating on shares of QuidelOrtho in a report on Wednesday, November 20th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $53.43.
Get Our Latest Stock Analysis on QuidelOrtho
Hedge Funds Weigh In On QuidelOrtho
Institutional investors and hedge funds have recently made changes to their positions in the business. Texas Permanent School Fund Corp boosted its holdings in QuidelOrtho by 0.6% in the second quarter. Texas Permanent School Fund Corp now owns 43,532 shares of the company's stock worth $1,446,000 after purchasing an additional 257 shares during the period. Balanced Rock Investment Advisors LLC lifted its position in shares of QuidelOrtho by 5.1% in the 2nd quarter. Balanced Rock Investment Advisors LLC now owns 6,784 shares of the company's stock worth $225,000 after buying an additional 329 shares during the last quarter. Algert Global LLC grew its position in shares of QuidelOrtho by 1.0% during the 2nd quarter. Algert Global LLC now owns 46,846 shares of the company's stock valued at $1,556,000 after buying an additional 450 shares during the last quarter. Hunter Perkins Capital Management LLC raised its stake in QuidelOrtho by 2.9% during the third quarter. Hunter Perkins Capital Management LLC now owns 18,588 shares of the company's stock worth $848,000 after acquiring an additional 530 shares during the period. Finally, Capital Performance Advisors LLP acquired a new position in QuidelOrtho in the third quarter valued at approximately $25,000. 99.00% of the stock is currently owned by hedge funds and other institutional investors.
About QuidelOrtho
(
Get Free Report)
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
